Mylan announced the launch of Estradiol Transdermal System, the generic version of NovartisVivelle-DOT.

Vivelle-DOT is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

RELATED: Oral and Transdermal Estrogen Dose Equivalents

Estradiol Transdermal System is available in 0.025mg/day, 0.0375mg/day, 0.05mg/day, 0.075mg/day, and 0.1mg/day (twice weekly) strengths.

For more information call (800) RX-MYLAN or visit